- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued based on future growth
Swiss Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
1 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Basilea Pharmaceutica
Market Cap: CHF 642.8m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
New
BSLN
CHF 52.30
7D
-6.1%
1Y
13.8%
Newron Pharmaceuticals
Market Cap: CHF 372.3m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 18.60
7D
-5.6%
1Y
82.0%